Citi Boosts Eli Lilly with Buy Rating, Eyes Growth
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
- Latest
- Trending
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
Recursion Pharmaceuticals merges with Exscientia to revolutionize drug discovery, bringing new treatments to market more quickly.
Novavax reports $415M in Q2 revenue with Sanofi's help, eyeing new vaccine launches and cost reductions.
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
Exscientia merges into Recursion to form a $850 million AI drug discovery powerhouse, focusing on oncology and rare diseases.
Formation Bio secures $372M Series D led by Sanofi to enhance AI-driven drug development, focusing on workflow automation and AI ...
France's stock market saw mixed outcomes; CAC 40 fell 0.77% while other indices grew. Top gainers: Publicis, Accor. Biggest laggards: ...
Goldman Sachs reveals that the European version of the Magnificent 7, known as GRANOLAS, trades at a 30% discount. These ...
European companies known as GRANOLAS have proven to be a lower-risk investment, matching the growth of highflying tech giants. With ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.